Trials / Withdrawn
WithdrawnNCT00877955
Bioequivalence Of A Test Alprazolam Sublingual Formulation Compared To A Commercial Sublingual Formulation
Open-label, Randomized, Single-dose, 2-way Crossover Bioequivalence Study Comparing A New Alprazolam Sublingual Tablet Formulation To A Reference Alprazolam Sublingual Tablet
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This study tests the assumption that the bioavailability of alprazolam from a new sublingual formulation is the same as that from sublingual formulation expected to be used commercially in Brazil.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | alprazolam sublingual tablet commercial | 0.5 mg sublingual tablet, single dose |
| DRUG | alprazolam sublingual tablet test | 0.5 mg tablet, single dose |
Timeline
- Start date
- 2012-09-01
- Primary completion
- 2012-10-01
- Completion
- 2012-10-01
- First posted
- 2009-04-08
- Last updated
- 2021-01-28
Source: ClinicalTrials.gov record NCT00877955. Inclusion in this directory is not an endorsement.